Neurodermatitis
Conditions
Interventions
Group B:Group B: Conventional treatment plus liposomal bupivacaine nerve block: Oral ebastine tablets, 10 mg QD (once daily) + topical halometasone cream (as needed) + single-dose liposomal bupivacain
Group C:Group C: Liposomal bupivacaine nerve block alone: Enrolled patients receive a single-dose liposomal bupivacaine (133 mg) ultrasound-guided nerve block at the Anesthesia and Surgery Center, adm
Group A:Group A: Conventional treatment group (oral antihistamine + topical corticosteroid): Oral ebastine tablets, 10 mg QD (once daily) + topical halometasone cream (as needed).
Sponsors
The Seventh Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Patients meeting the diagnostic criteria for neurodermatitis, with clearly defined lesion locations, and exclusion of other concurrent dermatological conditions; 2.Patients who have failed or relapsed after treatment with potent topical corticosteroids, or have relapsed following other guideline-recommended standard therapies; 3.Age 18-65 years; 4.With no significant comorbid systemic diseases, such as respiratory, circulatory, or immune system disorders
Exclusion criteria
Exclusion criteria: 1.Allergy to local anesthetics; 2.Concurrent severe dermatological or neurological disorders; 3.Unwillingness to provide informed consent; 4.Pregnancy or lactation; 5.Presence of psychiatric disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numerical rating scale,NRS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin-31;Interleukin-4;Interleukin-13;Standardized Scoring Form;Dermatology Life Quality Index (DLQI);Calcitonin gene related peptide(CGRP); | — |
Countries
China
Contacts
Public ContactChi Xinjin
The Seventh Affiliated Hospital Sun Yat-sen University
Outcome results
None listed